B · Normal
On September 21, Novo Nordisk’s Chief Scientific Officer (CSO) stated that at least five oral drug candidates are expected to enter the clinical development stage by the end of this year.
Related telegraphs
[Novo Nordisk responds to "Simeglutide reflux drugs": supports and fully coopera
09-22 11:06
[The concept of innovative drugs rebounded in shock, and Hokuriku Pharmaceutical
09-22 09:52
On September 21, Novo Nordisk stated that Mexico is the next market for Wegovy o
09-21 20:59
On September 21, the head of Novo Nordisk in the United States said that since J
09-21 20:19
On September 21, the CEO of Novo Nordisk stated that it would launch new innovat
09-21 16:32
On September 21, Novo Nordisk’s CEO stated that by 2030, the company’s productio
09-21 16:28
Comments